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Multiple Myeloma (MM) is a plasma cell malignancy characterized by uncontrolled proliferation of 
abnormal plasma cells in the bone marrow (BM). This disease is treatable but still incurable. The expected 
patient’s survival is approximately 3-5 years depending on disease state and treatment. Novel drugs, for 
example, the immunomodulatory drug thalidomide and proteasome inhibitor bortezomib or cellular 
treatment strategies like BM transplantation have been explored in the treatment of MM. However, they are 
not suitable for all patients due to age limitation. Despite various options of treatments, recurrence of the 
disease is common. Therefore, more effective treatment is still desirable. The main clinical features of MM 
disease are the accumulation of myeloma cells within the BM, the overproduction of monoclonal 
immunoglobulin (Ig) from the malignant myeloma cell clone, anemia, hypercalcemia and bone lesions. In the 
late stage of tumor progression, extramedullar tumor cell spreading also occurs.  
Components of the plasminogen-plasmin system, which are involved in blood clot dissolution, 
participate in tumor growth, invasion and metastasis. The urokinase-type and tissue-type plasminogen 
activator (uPA and tPA) are proteinases that convert plasminogen into plasmin, a key factor in fibrinolytic 
system, and are balanced by their endogenous inhibitors, the plasminogen activator inhibitor 1 or 2 (PAI-1, or 
PAI-2). Plasmin can render other proteolytic enzymes, like matrix metalloproteinase (MMP) -2 and -9, from 
its inactive into its active state. In MM patients, the increased production of MMP-2 and -9 was associated 
with tumor progression and MM cell homing to the BM. MMP inhibitors have been proposed for the 
treatment of MM, but severe side effects occurred in MMP inhibitor-treated patients. Various studies 
suggested that the fibrinolytic system might contribute to MM pathogenesis: Plasmin could activate 
  
cytokine/cytokine receptor like vascular endothelial growth factor, which could promote angiogenesis and 
support MM growth. Moreover, the increased level of receptor for uPA (uPAR or CD87), which is expressed on 
primary human MM cells, and its soluble form (suPAR) were suggested as a predictor for poor prognosis in 
MM patients. Recent studies also reported that primary malignant human myeloma cells express uPA. Here, 
we hypothesize that fibrinolytic factors play a role in MM cell growth as they either can control the activation 
of disease-associated proteases like MMPs or can directly modulate other molecular targets (cytokine, 
receptors or extracellular matrix molecules) involved in MM.  
 
 
 
 
 
 
 
 
 
 
 
Figure 1: The fibrinolytic system 
 
 
First the expression of fibrinolytic factors on human and murine MM cell lines was examined using 
qPCR. Whereas human MM cell lines showed low or no expression of fibrinolytic factors, the murine 
plasmacytoma cell lines sp2/0-Ag14 and B53 expressed uPA, uPAR, and/or PAI-1. Because the proliferation 
and survival of MM cell require not only autocrine, but also e.g. BM stromal cells paracrine, stromal cell lines 
were also included in the analysis. Both human and mouse stromal cell lines expressed uPA, tPA, uPAR, and 
PAI-1. Because B53 cells resembled most closely the fibrinolytic factor expression in human primary MM cells 
according to recent reports, we chose the murine B53 cell line for further studies. B53 cells secrete IgE 
allowing us to evaluate the tumor burden in vivo using ELISA assays and responded to treatment with 
common MM drugs like bortezomib and doxorubicin. To study the role of the fibrinolytic pathway for MM 
progression in vivo, we established a murine syngeneic MM model by injecting B53 cells intravenously at a 
  
concentration of 106 cells/mouse into 6-week-old female CB6F1/Slc (CBF1) mice. The number of BM 
mononucleated cells (BMMNC) was decreased in MM-bearing mice over time. Infiltrating B53 cells were 
detected on hematoxylin & eosin stained BM, spleen and liver tissue sections and were quantified by FACS 
using the antigen expression pattern CD138+H2kd+/H2kb- to identify MM B53 cells. B53 organ infiltration 
varied significantly between mice, making this method unsuitable to monitor disease progression. Osteolytic 
lesions could not be observed by X-ray imaging. An increase in the expression of tPA, uPAR, and PAI-1 was 
found on BMMNC isolated from MM-bearing when compared to non-MM bearing mice as determined by 
qPCR. In accordance with reports in humans, suPAR levels rose during disease progression in MM-bearing 
mice. Interestingly, active plasmin plasma levels increased over time in MM-bearing mice, indicating that the 
fibrinolytic system is activated during disease progression in the murine MM model in vivo. These data 
prompted us to evaluate whether plasmin inhibition could be a novel treatment modality for MM by using the 
selective plasmin inhibitor named YO-2.  
The plasmin inhibitor YO-2 has been reported a) to selectively inhibit active plasmin by binding at 
the catalytic site of plasmin and b) to induce apoptosis in solid cancer cell lines. Next, we examined whether 
the plasmin inhibitor YO-2 showed anti-MM activity in vitro. YO-2 treatment (IC50 = 20 μM) inhibited 
proliferation and induced apoptosis in murine B53 and human RPMI8226 MM cells as determined by cell 
counting (tryphan blue dye extinction) and Annexin V-PI assay, respectively. We are currently investigating 
which caspases are activated after YO-2 treatment. Given that YO-2 blocked MM growth in vitro, we next 
studied its effect on MM cell growth in vivo. The RPMI8226 xenograft murine MM model was established by 
injecting 4x106 luciferase labeled RPMI8226 cells subcutaneously into immunodeficient NOD/SCID mice. 
Mice were injected daily with/without YO-2 intraperitoneally at a concentration of 3.75 mg/kg of body weight 
(BW). Tumor growth was similar for YO-2-treated and carrier-treated RPMI8226 xenografted mice as 
determined by size measurement and luciferase signal detection suggesting that in YO-2 treatment could not 
prevent MM cell progression in vivo.  
We next determined the YO-2 responsiveness in B53-injected CBF1 mice. Survival and IgE plasma 
levels had been identified as reliable parameters to monitor disease progression in this model. Although 
plasmin activation was suppressed during disease progression in YO-2-treated MM-bearing mice, no 
difference in the survival rate, the tumor load and the tissue infiltration were found for YO-2 treated 
compared to control group. YO-2 treatment did not alter the expression of fibrinolytic factors (tPA, uPA, 
PAI-1) in BMMNCs as determined by qPCR. Similar plasma levels for PAI-1, total uPA, soluble-uPAR were 
  
found in YO-2 or carrier-treated groups. To rule out that an insufficient concentration of YO-2 caused the 
failure of YO-2 treatment in controlling MM growth in vivo, we tested higher concentrations of YO-2 in the 
B53 murine MM model (7.5mg/kg of BW = 2x, or 15mg/kg of BW = 4x). Although active plasmin was almost 
completely blocked in treated mice, the 2x YO-2 treatment could not prevent disease progression. And at the 
highest 4x YO-2 concentration, it even accelerated the death of MM carrying mice. The reason for the 
increased mortality is currently unclear, but thromboembolic events might have occurred. Similar to data 
obtained using YO-2, treatment with the plasmin inhibitor tranexamic acid could not prevent MM 
progression. Next, we tested whether YO-2 in combination with MM-active drugs can control tumor growth. 
Bortezomib was chosen because bortezomib-treated MM patients showed a lower incidence of venous 
thromboembolism suggesting that bortezomib might stimulate fibrinolysis. When B53-bearing MM mice were 
treated with a combination of bortezomib and YO-2 or bortezomib alone, the addition of YO-2 significantly 
impaired survival in MM mice. In summary, our data suggest that although fibrinolytic factors are elevated 
in murine models of MM, pharmacological inhibition of plasmin was not able to prevent the progression of 
this aggressive disease.  
 
 
 
